Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112129 - ENHANCED TARGETED DELIVERY OF THERAPEUTIC AGENTS

Publication Number WO/2020/112129
Publication Date 04.06.2020
International Application No. PCT/US2018/063242
International Filing Date 30.11.2018
IPC
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/66 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
66the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K 47/65 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/62 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
CPC
A61K 47/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
A61K 47/65
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
66the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Applicants
  • PRISM | PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDICINE [US]/[US]
Inventors
  • SCHNITZER, Jan, E.
  • OH, Philip, Sung-Whan
  • CHRASTINA, Adrian
  • LEVIN, Michael
  • OLENYUK, Bogdan, Z.
  • KOTA, Rajesh
Agents
  • CHAMBERS, Daniel, M.
  • WHITTAKER, Michael, A.
Priority Data
62/773,32230.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ENHANCED TARGETED DELIVERY OF THERAPEUTIC AGENTS
(FR) ADMINISTRATION CIBLÉE AMÉLIORÉE D'AGENTS THÉRAPEUTIQUES
Abstract
(EN)
Methods and compositions for enhancing the therapeutic activity of agents at low doses as a result of improved targeted drug delivery, namely precision delivery, are described. The methods and compositions can be used to decrease the effective administered amounts of active therapeutic agents via precision delivery to targets capable of mediating active transport across the biological barrier formed by the vasculature that lines blood vessels. Antibodies (and other targeting agent species) to precisely deliver an active ingredient (i.e., a therapeutic agent) to cells expressing, for example, a target protein on their cell membranes, are also described, as are methods of treating disease.
(FR)
L'invention concerne des méthodes et des compositions pour améliorer l'activité thérapeutique d'agents à faibles doses suite à une administration de médicament ciblée améliorée, à savoir, une administration de précision. Les méthodes et les compositions peuvent être utilisées pour diminuer les quantités efficaces d'agents thérapeutiques actifs administrées par l'administration de précision à des cibles susceptibles de médier le transport actif à travers la barrière biologique formée par le système vasculaire qui conduit les vaisseaux sanguins. L'invention concerne également des anticorps (et autres espèces d'agents de ciblage) pour administrer précisément un principe actif (c'est-à-dire, un agent thérapeutique) à des cellules exprimant, par exemple, une protéine cible sur leurs membranes cellulaires, ainsi que des méthodes de traitement d'une maladie.
Latest bibliographic data on file with the International Bureau